Last reviewed · How we verify
BIMZELX (BIMEKIZUMAB-BKZX)
BIMZELX (generic name: BIMEKIZUMAB-BKZX) is a drug developed by UCB INC. It is currently FDA-approved for Moderate to severe plaque psoriasis, Active psoriatic arthritis, Active non-radiographic axial spondyloarthritis.
Bimekizumab, also known as BIMZELX, is an interleukin 17A inhibitor, a type of antibody that targets Interleukin-17A. It is being studied in clinical trials for various conditions, including psoriasis, psoriasis arthritis, and palmoplantar pustulosis.
At a glance
| Generic name | BIMEKIZUMAB-BKZX |
|---|---|
| Sponsor | UCB INC |
| Target | Interleukin-17A, Interleukin-17F, Interleukin-17AF |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Moderate to severe plaque psoriasis
- Active psoriatic arthritis
- Active non-radiographic axial spondyloarthritis
- Active ankylosing spondylitis
- Moderate to severe hidradenitis suppurativa
Common side effects
- Infections
- Upper respiratory tract infections
- Candida infections (oral candidiasis, oropharyngeal candidiasis, oral fungal infection, fungal pharyngitis, oropharyngitis fungal)
- Passive suicidal ideation
- Neutropenia
- Eczema
- Otitis externa
- Otitis media
- Pyrexia
Serious adverse events
- Serious infections
- Completed suicide
- Suicide attempts
Drug interactions
- CYP450 substrates
Key clinical trials
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (Phase 2)
- A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers (Phase 4)
- Bimzelx (Bimekizumab) For The Treatment Of Adult Onset Pityriasis Rubra Pilaris: A Single Arm, Open?Label, Exploratory Trial (Phase 4)
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study With Open-Label Extension to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulos (Phase 3)
- Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis Who Have an Inadequate Skin Response to Anti-IL23 Therapy (Phase 4)
- Dose Reduction of the New Generation Biologicals (IL17 and IL23 Inhibitors) in Psoriasis: A Pragmatic, Multicentre, Randomized, Controlled, Non-inferiority Study - BeNeBio Study (Phase 4)
- A Multicenter Open-label, Prospective Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BIMZELX CI brief — competitive landscape report
- BIMZELX updates RSS · CI watch RSS
- UCB INC portfolio CI
Frequently asked questions about BIMZELX
What is BIMZELX?
BIMZELX (BIMEKIZUMAB-BKZX) is a pharmaceutical drug developed by UCB INC, indicated for Moderate to severe plaque psoriasis, Active psoriatic arthritis, Active non-radiographic axial spondyloarthritis.
What is BIMZELX used for?
BIMZELX is indicated for Moderate to severe plaque psoriasis, Active psoriatic arthritis, Active non-radiographic axial spondyloarthritis, Active ankylosing spondylitis, Moderate to severe hidradenitis suppurativa.
Who makes BIMZELX?
BIMZELX is developed and marketed by UCB INC (see full UCB INC pipeline at /company/ucb).
What is the generic name of BIMZELX?
BIMEKIZUMAB-BKZX is the generic (nonproprietary) name of BIMZELX.
What development phase is BIMZELX in?
BIMZELX is FDA-approved (marketed).
What are the side effects of BIMZELX?
Common side effects of BIMZELX include Infections, Upper respiratory tract infections, Candida infections (oral candidiasis, oropharyngeal candidiasis, oral fungal infection, fungal pharyngitis, oropharyngitis fungal), Passive suicidal ideation, Neutropenia, Eczema. Serious adverse events: Serious infections, Completed suicide, Suicide attempts.
What does BIMZELX target?
BIMZELX targets Interleukin-17A, Interleukin-17F, Interleukin-17AF.
Related
- Target: All drugs targeting Interleukin-17A, Interleukin-17F, Interleukin-17AF
- Manufacturer: UCB INC — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Moderate to severe plaque psoriasis
- Indication: Drugs for Active psoriatic arthritis
- Indication: Drugs for Active non-radiographic axial spondyloarthritis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing